Tue, May 13, 12:03 PM (39 days ago)
**NeuroOne Medical Technologies Corporation (NMTC, Ticker: NMTC)** **Quarterly Financial Health and Performance (Q1 2025):** NeuroOne Medical Technologies Corporation reported a net loss of $2.3 million for Q1 2025, an improvement from the $2.9 million loss in Q1 2024. Product revenue increased by 0.7% to $1.4 million, with a significant improvement in gross profit margin to 55.6% from 28.3% in the previous year, driven by higher-margin OneRF Products. Operating expenses decreased by 3.1% to $3.5 million, primarily due to lower administrative and legal costs. Research and development expenses increased by 18.4% to $1.5 million, reflecting ongoing product development activities. The company recognized a $0.4 million benefit from the fair value change in warrant liability. As of March 31, 2025, NeuroOne had $1.3 million in cash and cash equivalents. Subsequent to the quarter, the company received approximately $8.2 million from the April 2025 Financing. The company's future operations and liquidity depend on its ability to generate revenue from commercial sales and secure additional funding. Global economic uncertainties and supply chain constraints pose risks to the company's financial performance. NeuroOne's strategic focus includes commercializing its thin film electrode technology and expanding its product portfolio. The company's ability to achieve profitability will depend on securing regulatory approvals and generating sufficient product sales.